Multiple Sclerosis

The AJMC^® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.

Latest News

BMI - Olivier Le Moal

Study Finds Obesity May Worsen Multiple Sclerosis: Genetic Analysis Points to Causal Link

By Kimberly Rath, PharmD

November 21st 2024

A new study aimed at exploring the relationship between obesity and multiple sclerosis severity using genetic data finds that higher BMI and other obesity measures were associated with increased disability progression in patients with MS.

Doctor examining MRI images of multiple sclerosis MS | Image Credit: © New Africa - stock.adobe.com

Lesion Repair, Damage Processes Correlate With MS Disease Characteristics

By Jared Kaltwasser

November 11th 2024

Neurologic disease concept | image credit: ralwel - stock.adobe.com

Fexagratinib in MS Shows Promise for Human Use

By Jared Kaltwasser

November 9th 2024

MS word cloud | Image Credit: © arloo-stock.adobe.com

Exploring Metabolic Links to Cognitive Impairment in MS

By Gayle Turim Dickstein

November 8th 2024

Fingolimod | Image Credit: © María Pilar Martínez - stock.adobe.com

Fingolimod-Induced Heart Rate Slowing Tied to Parasympathetic Dominance in MS

By Jared Kaltwasser

October 26th 2024

Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain key insights into managing and understanding this condition.

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain valuable insights into managing and understanding this complex condition.

Continuing Medical Education

November 21st 2024

Assessing the Treatment Landscape for Multiple Sclerosis to Better Individualize Care

1.5 Credits / Neurology

November 21st 2024

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases

November 21st 2024

The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of Early Intervention, Patient-Centered Care, and Disease-Modifying Therapies in Slowing Disease Progression

1.0 Credit / Neurology

November 21st 2024

Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis

1.0 Credit / Immunology, Neurology

November 21st 2024

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

More News

March 17th 2016

Impact of Cost Sharing on Specialty Drug Utilization and Outcomes: A Review of the Evidence and Future Directions

Jalpa A. Doshi, PhD Pengxiang Li, PhD Vrushabh P. Ladage, BS Amy R. Pettit, PhD Erin A. Taylor, PhD, MSPH

The authors review published evidence regarding associations between high cost sharing for specialty pharmaceuticals indicated for rheumatoid arthritis, multiple sclerosis, and cancer, and their utilization.

April 18th 2015

First Generic Version of MS Drug Copaxone Approved

After months of anticipation, the FDA has approved a generic version of Copaxone, which means Momenta Pharmaceuticals and Sandoz can now sell a knockoff of a drug that generated more than $3.1 billion in sales in the US last year.

January 1st 2015

Implications for Multiple Sclerosis in the Era of the Affordable Care Act: The Shifting Managed Care Landscape

A. Scott Mathis, PharmD Gary M. Owens, MD

December 28th 2014

Implications for Multiple Sclerosis in the Era of the Affordable Care Act: An Evolving Treatment Paradigm

Luigi Brunetti, PharmD, MPH Samuel F. Hunter, MD, PhD

December 28th 2014

Implications for Multiple Sclerosis in the Era of the Affordable Care Act: A Clinical Overview

Megan Maroney, PharmD, BCPP Samuel F. Hunter, MD, PhD

December 16th 2014

Participating Faculty: Implications for Multiple Sclerosis in the Era of the Affordable Care Act: A Clinical and Managed Care Perspective [CME/CPE]

Dr Paul Wicks Points to the Benefits of Technology in MS Research

September 13th 2014

Dr Paul Wicks Points to the Benefits of Technology in MS Research

Paul Wicks, PhD, vice president of innovation at PatientsLikeMe, discussed the benefits of using technology in multiple sclerosis research by patients, providers, researchers, and other decision-makers.

Making Treatment Decisions When There Is an Abundance of Options

September 13th 2014

Making Treatment Decisions When There Is an Abundance of Options

Laura Joszt, MA

Despite the benefit of having more choices than ever before to treat patients with multiple sclerosis, the abundance of options has led to more complexity, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.

The Power of Treating Patients as Partners in MS Clinical Research

September 13th 2014

The Power of Treating Patients as Partners in MS Clinical Research

Laura Joszt, MA

As a medium, the Internet neither helps nor harms in multiple sclerosis care - what matters is how clinicians and patients engage in that medium, according to Paul Wicks, PhD, vice president of innovation at PatientsLikeMe.

Dr Alasdair Coles on the Effectiveness of Alemtuzumab in Treating MS

September 12th 2014

Dr Alasdair Coles on the Effectiveness of Alemtuzumab in Treating MS

At this year's ECTRIMS conference in Boston, Alasdair Coles, MD, University of Cambridge, discussed alemtuzumab and its effectiveness in treating multiple sclerosis.

Genzyme's Lemtrada Reports Positive Results After 4 Years

September 12th 2014

Genzyme's Lemtrada Reports Positive Results After 4 Years

Laura Joszt, MA

The second year of the extension study of Lemtrada (alemtuzumab) for multiple sclerosis reported positive interim results with 70% of patients not requiring a third course of treatment.

Improving Patient-Clinician Communication and Treatment Adherence

September 12th 2014

Improving Patient-Clinician Communication and Treatment Adherence

Laura Joszt, MA

Although there have been significant advances in multiple sclerosis management, patient preferences need to be taken into account before choosing treatment, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.

Engaging Patients in Their Own Treatment Decisions

September 12th 2014

Engaging Patients in Their Own Treatment Decisions

Laura Joszt, MA

Patients with multiple sclerosis want to be actively engaged in their treatment decisions, which will help their long-term health and medication adherence, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.

Heterogeneity of MS Makes New Disease Biomarker Discovery Difficult

September 12th 2014

Heterogeneity of MS Makes New Disease Biomarker Discovery Difficult

Laura Joszt, MA

The treatment landscape for multiple sclerosis continues to get more complex month to month, which makes biomarker discovery increasingly important for treating the disease, said Suhayl Dhib-Jalbut, MD, professor at the Rutgers University Robert Wood Johnson Medical School, during his session at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.

PML is Treatable in MS, but Long-Term Function Can Remain Affected

September 11th 2014

PML is Treatable in MS, but Long-Term Function Can Remain Affected

Laura Joszt, MA

Although the survival rate of natalizumab-associated progressive multifocal leukoencephalopathy (PML) is better than PML in HIV patients, long-term they may need some assistance and care, Ralf Gold, Ruhr University Bochum in Germany, said at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.

Using Advanced Imaging Techniques to Better Understand MS Progression

September 11th 2014

Using Advanced Imaging Techniques to Better Understand MS Progression

Laura Joszt, MA

Advanced imaging techniques are becoming necessary to further understanding of the progression of multiple sclerosis, according to presenters at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts, from September 10-13.

Collaborative Decision Making Tops Efficacy for MS Patients

September 11th 2014

Collaborative Decision Making Tops Efficacy for MS Patients

Laura Joszt, MA

When choosing treatment for a patient, whether he or she has a clinically isolated syndrome or clinically definite multiple sclerosis, providers need to establish a collaborative relationship, according to speakers at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.

April 16th 2014

The Burden of Soaring Prices of Specialty Drugs

Even as the cost of prescription drugs has plummeted for many Americans, a small slice of the population is being asked to shoulder more and more of the cost of expensive treatments for diseases like cancer and hepatitis C, according to a report to be released on Tuesday by a major drug research firm.

March 3rd 2014

Chronically Ill Face High Out-of-Pocket Costs

Those with chronic illnesses such as leukemia, hepatitis C, and multiple sclerosis may face a significant increase in their out-of-pocket expenses for specialty drugs. This is because payers are replacing fixed-dollar copayments with coinsurance rates that require patients to contribute a higher percentage of the cost for their specialty medications.

February 4th 2014

Pharmacy Benefit Management Institute Conference Highlights

This week AJMC is covering session highlights from the PBMI Annual Drug Benefit conference.

November 30th 2013

Impact of Diagnosis and Early Treatment on the Course of Multiple Sclerosis

Katia Noyes, PhD, MPH Bianca Weinstock-Guttman, MD

November 30th 2013

Choosing the Best Treatment for Multiple Sclerosis: Comparative Effectiveness, Safety, and Other Factors Involved in Disease-Modifying Therapy Choice

Laura E. Happe, PharmD, MPH

November 30th 2013

An Update on New and Emerging Therapies for Relapsing-Remitting Multiple Sclerosis

Bianca Weinstock-Guttman, MD

November 30th 2013

Participating Faculty: Current Topics in Multiple Sclerosis

November 29th 2013

Post Test: A Data-Driven Approach to Improving Clinical and Economic Outcomes in Multiple Sclerosis

November 26th 2013

Managed Care Aspects of Managing Multiple Sclerosis

Gary M. Owens, MD

November 25th 2013

Management of Multiple Sclerosis

Amy Perrin Ross, APN, MSN, CNRN, MSCN

November 24th 2013

Participating Faculty: A Data-Driven Approach to Improving Clinical and Economic Outcomes in Multiple Sclerosis

November 24th 2013

Multiple Sclerosis Update

Clyde E. Markowitz, MD

Patricia Coyle, MD, Discusses Treatment of Multiple Sclerosis

October 29th 2013

Patricia Coyle, MD, Discusses Treatment of Multiple Sclerosis

Patricia Coyle, MD, director, MS Comprehensive Care Center, Stony Brook Neurosciences Institute, professor and vice chair of clinical affairs, Department of Neurology, SUNY at Stony Brook, says that prognostically, the earlier you treat multiple sclerosis the better.

...

13 14 15 16 17 18 19 20 21 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions